大青龍湯與清冠一號遠距COVID-19治療與預防個案報告

Daqinglong Tang and NRICM101 on COVID-19 Treatment and Prevention by Taiwan Telemedicine Oversea Case Reports

10.6516/TJTCM.202203/SP_25.0002

廖芳儀(Fang-I Liao)；林恭儀(Justin Kung Yi LIN)；黃建榮(Chien-Jung Huang)；周艷秋(Yanqiu Zhou)；Alexander T. H. Wu

傷寒雜病論 ； 大青龍湯 ； 中藥清冠一號 ； 遠距醫療 ； 新冠肺炎 ； Daqinglong Tang ； NRICM101 ； telemedicine ； COVID-19

中醫藥研究論叢

25卷特刊（2022 / 03 / 05）

13 - 20

繁體中文

台灣移居美國德州海外華僑家庭，在多方傳染源下，發生一家四口中三名家庭成員群聚感染COVID-19疫情。適時衛福部公告國內中藥緊急授權使用，台灣家人得知後接洽本醫療單位，安排遠距視訊，給予海外中醫醫療援助。歷經詳細遠距診療後，以經方治療思路，給予大青龍湯與輔助緊急授權中藥清冠一號，有效緩解SARS-COV-2病毒感染造成的呼吸道、嗅覺症狀、並預防保護了密集接觸家庭照顧者的傳染性。台灣健保與防疫成績在國際間，享有盛名，如何推動外交醫療與海外醫療，在疫病大流行期間進行中醫海外遠距醫療，值得政府有關單位借鏡參考。

Taiwanese immigrated family in Texas, USA., infected by multiple sources of SARS COV-2, three members of a family of four were confirmed as the COVID-19 community-based cluster infection came to our traditional telemedicine clinic. At the same time, Taiwan government, the Ministry of Health and Welfare, legally consented to the emergency use authorization of traditional medicine NRICM101. One cognate in Taiwan came to Taipei traditional clinic to arrange telemedicine for his oversea son and all other members. Through messenger app evaluation and diagnosis, we prescribed Daqinglong Tang and NRICM101 as the major and preventive formulars to release the respiratory system and anosmia induced by COVID-19, in all quarantine persons and healthy caregiver successfully. Taiwan's collective efforts of COVID-19 is so well-known globally in her health insurance coverage and epidemic prevention. The diplomatic medical aid and traditional medicine overseas telemedicine strategy in our model were highly valuable and worthy of official development in the global future.

1. 林恭儀,黃建榮,鄭宏足,陳文戎,陳曉鈞,王翊錞,吳詩儀,盧景裕,劉姿妤(2020)。新型冠狀病毒（SARS-CoV-2）感染中醫整合臨床處置暫行指引第一版。中醫藥研究論叢，23(2)，181-191。
   連結：
2. 曾馨儀,陳怡仁,林邑璁(2021)。美國胸腔醫學會及感染症醫學會之社區型肺炎診斷及治療準則介紹。臨床醫學月刊，88(2)，490-499。
   連結：
3. 劉虹伶,巫孟萱,李聰界(2021)。探討新型冠狀病毒肺炎指引與常用中醫處方。中醫內科醫學雜誌，19(2)，1-12。
   連結：
4. 衛生福利部國家中醫藥研究所(2020)。《新型冠狀病毒病中醫臨床分期治療指引》公告。中醫藥雜誌，31(1)，1-3。
   連結：
5. 衛生福利部核准「臺灣清冠一號濃縮製劑」專案製造，應經中醫師處方，民眾勿自行購買服用。衛生福利部中醫藥司。2021/12/5。取得網址：https://www.mohw.gov.tw/cp-16-60830-1.html
6. (2021)。羅氏、賽默飛 SARS-CoV-2 檢測試劑獲 FDA 緊急授權。環球生技月刊
7. Emergency use ICD codes for COVID-19 disease outbreak. W.H.O. 2021/12/29. Available at: https://www.who.int/standards/classifications/classification-of-diseases/emergency-use-icd-codes-for-covid-19-disease-outbreak.
8. 因應社區傳播有擴大趨勢，指揮中心自即日起至 5 月 28 日提升雙北地區疫情警戒至第三級，加嚴、加大全國相關限制措施，嚴守社區防線。衛生福利部疾病管制署。2021/12/27。取得網址：https://www.cdc.gov.tw/Bulletin/Detail/E7bi2j8UYj1Rmz73OPE7Yg?typeid=9。
9. 檢疫隔離 . Centers for Disease Control and Prevention COVID-19. U.S.A.. https://chinese.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-isolation.html. Available at 2021/12/27.
10. （清）柯琴。柯琴：傷寒來蘇集，清。中國哲學書電子化計劃。2021/12/30。取得網址：https://ctext.org/library.pl?if。https://ctext.org/library.pl?if=gb&res=96588&by_title=%E5%82%B7%E5%AF%92%E4%BE%86%E8%98%87%E9%9B%86
11. （清）鄒樹。鄒樹：本經疏證，清。中國哲學書電子化計劃。2021/12/30。取得網址：https://ctext.org/library.pl?if。https://ctext.org/library.pl?if=gb&file=29447&page=26
12. Aluisio, AR,Zhu, E,Gil, G,Kenyon, T,Uzevski, V,Levine, AC(2020).Academic-humanitarian partnerships: leveraging strengths to combat COVID-19.Glob Health Action,13(1),1797296.
13. An, X,Zhang, Y,Duan, L,Jin, D,Zhao, S,Zhou, R,Duan, Y,Lian, F,Tong, X(2021).The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19.Biomed Pharmacother,137,111267.
14. Gudziol, H,Kirschstein, T,Pletz, MW,Weis, S,Guntinas-Lichius, O,Bitter, T,CoNAN study group(2021).High prevalence of long-term olfactory dysfunction confirmed by olfactory testing after a community COVID-19 outbreak.HNO,1-8.
15. Lechien, JR,Chiesa-Estomba, CM,De Siati, DR(2020).Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study.Eur Arch Otorhinolaryngol
16. Li, Y,Chu, F,Li, P,Johnson, N,Li, T,Wang, Y,An, R,Wu, D,Chen, J,Su, Z,Gu, X,Ding, X(2021).Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification.J Ethnopharmacol,271,113854.
17. Shadmi, E,Chen, Y,Dourado, I,Faran-Perach, I,Furler, J,Hangoma, P,Hanvoravongchai, P,Obando, C,Petrosyan, V,Rao, KD,Ruano, AL,Shi, L,de Souza, LE,Spitzer-Shohat, S,Sturgiss, E,Suphanchaimat, R,Uribe, MV,Willems, S(2020).Health equity and COVID-19: global perspectives.Int J Equity Health,19(1),104.
18. The Lancet(2020).COVID-19 in Latin America: a humanitarian crisis.Lancet,396(10261),1463.
19. Tsai, KC,Huang, YC,Liaw, CC,Tsai, CI,Chiou, CT,Lin, CJ,Wei, WC,Lin, SJ,Tseng, YH,Yeh, KM,Lin, YL,Jan, JT,Liang, JJ,Liao, CC,Chiou, WF,Kuo, YH,Lee, SM,Lee, MY,Su, YC(2021).A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study.Biomed Pharmacother,133,111037.
20. Wu, H,Gong, K,Qin, Y,Yuan, Z,Xia, S,Zhang, S,Yang, J,Yang, P,Li, L,Xie, M(2021).In silico analysis of the potential mechanism of a preventive Chinese medicine formula on coronavirus disease 2019.J Ethnopharmacol,275,114098.